XML 40 R25.htm IDEA: XBRL DOCUMENT
v3.24.0.1

STOCK-BASED COMPENSATION | 12 Months Ended
--- | ---
Dec. 31, 2023
STOCK-BASED COMPENSATION |
STOCK-BASED COMPENSATION | 18.STOCK-BASED COMPENSATION On April 12, 2021, the Company’s stockholders approved the 2021 Omnibus Equity Incentive Plan (the “2021 Omnibus Equity Plan”), which became effective on April 22, 2021, upon pricing of its initial public offering. The 2021 Omnibus Equity Plan provides for the issuance of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based and cash-based awards. The maximum grant date fair value of cash and equity awards that may be awarded to a non-employee director under the 2021 Omnibus Equity Plan during any one fiscal year, together with any cash fees paid to such non-employee director during such fiscal year, is $750,000. On May 2, 2023, at the 2023 annual meeting of stockholders the Company, the stockholders approved the first amendment (the “Equity Plan First Amendment”) to the Latham Group, Inc. 2021 Omnibus Equity Plan, which was previously approved by the Board of Directors of the Company. The Equity Plan First Amendment became effective upon stockholder approval, and provides for (i) an increase by 8,000,000 shares of the share pool, i.e. the maximum number of shares of the Company’s common stock that may be issued pursuant to awards granted under the 2021 Omnibus Equity Plan, (ii) a prohibition on recycling of shares withheld or remitted to pay taxes for all awards, (iii) a minimum vesting period of one year for all awards, with an exception for shares representing 5% of the share pool, and (iv) a prohibition on the transfer of stock options and stock appreciation rights for value or to third-party financial institutions without stockholder approval. Except as amended by the Equity Plan First Amendment, the other terms of the 2021 Omnibus Equity Plan remain in full force and effect. Subsequent to the Equity Plan First Amendment, the maximum aggregate number of shares reserved for issuance under the 2021 Omnibus Equity Plan is 21,170,212 shares. The following table summarizes the Company’s stock-based compensation expense (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended | ​
​ | ​ | December 31, | ​
​ | ​ | 2023 | ​ | 2022 |  | 2021 | ​
Cost of sales | ​ | $ | 81 | ​ | $ | 3,762 | ​ | $ | 8,697 | ​
Selling, general, and administrative | ​ |  | 18,723 | ​ |  | 46,872 | ​ |  | 120,078 | ​
​ | ​ | $ | 18,804 | ​ | $ | 50,634 | ​ | $ | 128,775 | ​
​ The recognized income tax benefit related to stock-based compensation was $0.5 million for the year ended December 31, 2023. The recognized income tax benefit related to stock-based compensation was $0.8 million for the year ended December 31, 2022. The recognized income tax benefit related to stock-based compensation was $0.1 million for the year ended December 31, 2021. As of December 31, 2023, total unrecognized stock-based compensation expense related to all unvested stock-based awards was $7.4 million, which is expected to be recognized over a weighted-average period of 1.53 years. The following table sets forth the significant assumptions used in the Black-Scholes option-pricing model on a weighted-average basis to determine the fair value of stock appreciation rights awards granted:
​ | ​ | ​ | ​
​ | ​ | Year Ended | ​
​ |  | December 31, 2023
Risk-free interest rate | ​ | 3.54 | %
Expected volatility | ​ | 40.34 | %
Expected term (in years) | ​ | 6.25 | ​
Expected dividend yield | ​ | 0.00 | %
​ The following table sets forth the significant assumptions used in the Black-Scholes option-pricing model on a weighted-average basis to determine the fair value of option awards granted: ​
​ | ​ | ​ | ​
​ | ​ | Year Ended | ​
​ | ​ | December 31, 2022
Risk-free interest rate |  | 2.06 | %
Expected volatility |  | 39.68 | %
Expected term (in years) |  | 6.25 | ​
Expected dividend yield |  | 0.00 | %
​ No stock options were granted under this plan during the year ended December 31, 2023. ​ Restricted Stock Awards The following table represents the Company’s restricted stock awards activity during the year ended December 31, 2023: ​
​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted-
​ | ​ | ​ | ​ | Average Grant-
​ |  | Shares |  | Date Fair Value
Outstanding at January 1, 2023 |  | 2,576,219 | ​ | $ | 19.00
Granted |  | — | ​ |  | —
Vested |  | (2,377,883) | ​ |  | 19.00
Forfeited |  | (155,450) | ​ |  | 19.00
Outstanding at December 31, 2023 |  | 42,886 | ​ | $ | 19.00
​ Restricted Stock Units The following table represents the Company’s restricted stock units activity during the year ended December 31, 2023: ​
​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | Weighted-
​ | ​ | ​ | ​ | Average Grant-
​ | ​ | Shares | ​ | Date Fair Value
Outstanding at January 1, 2023 |  | 617,941 | ​ | $ | 8.37
Granted |  | 2,345,746 | ​ |  | 3.18
Vested |  | (465,863) | ​ |  | 7.63
Forfeited |  | (262,345) | ​ |  | 3.90
Outstanding at December 31, 2023 |  | 2,235,479 | ​ | $ | 3.60
​ ​ Stock Options The following table represents the Company’s stock option activity during the year ended December 31, 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ |  | ​ | Weighted- |  | Weighted- |  | ​ | ​
​ | ​ | ​ | ​ | ​ | Average | ​ | Average | ​ | ​ | ​
​ | ​ | ​ | ​ | Exercise Price | ​ | Remaining | ​ | Aggregate
​ |  | Shares |  | per Share |  | Contract Term |  | Intrinsic Value
​ |  | ​ |  | ​ | ​ | ​ | (in years) | ​ | (in thousands)
Outstanding at January 1, 2023 |  | 1,914,670 | ​ | $ | 14.85 |  | ​ | ​ | ​ | ​
Granted |  | — | ​ | ​ | — |  |  | ​ |  |
Exercised |  | — | ​ |  | — |  |  | ​ |  |
Forfeited |  | (311,344) | ​ |  | 11.37 |  |  | ​ |  |
Expired | ​ | (82,922) | ​ | ​ | 17.75 | ​ | ​ | ​ | ​ | ​
Outstanding at December 31, 2023 |  | 1,520,404 | ​ | $ | 15.40 |  | 7.94 | ​ | $ | —
Vested and expected to vest at December 31, 2023 |  | 1,520,404 | ​ | $ | 15.40 |  | 7.94 | ​ | $ | —
Options exercisable at December 31, 2023 |  | 521,173 | ​ | $ | 16.38 |  | 7.77 | ​ | $ | —
​ The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock. No stock options were granted during the year ended December 31, 2023. The weighted average grant-date fair value of stock options granted during the year ended December 31, 2022 was $5.53 per share. ​ Stock Appreciation Rights During the quarter ended April 1, 2023, as a portion of the annual equity award grants to the Company’s executive officers, the Compensation Committee of the Board of Directors approved stock appreciation rights for an aggregate of 790,181 shares of the Company’s common stock, with a strike price of $3.24 per share (the “Contingent Grants”). At the time of such approval, the Company did not have enough shares of the Company’s common stock in the share pool under the 2021 Omnibus Equity Plan to support such grant. As of April 1, 2023, the Contingent Grants remained subject to stockholder approval of the Equity Plan First Amendment. On May 2, 2023, following stockholder approval of the Equity Plan First Amendment, the foregoing stock appreciation right awards became effective without condition. The following table represents the Company’s stock appreciation rights activity during the year ended December 31, 2023:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ |  | ​ | Weighted- |  | Weighted- |  | ​ | ​
​ | ​ | ​ | ​ | ​ | Average | ​ | Average | ​ | ​ | ​
​ | ​ | ​ | ​ | Exercise Price | ​ | Remaining | ​ | Aggregate
​ |  | Shares |  | per Share |  | Contract Term |  | Intrinsic Value
​ |  | ​ |  | ​ | ​ | ​ | (in years) | ​ | (in thousands)
Outstanding at January 1, 2023 |  | — | ​ | $ | — |  | ​ | ​ | ​ | ​
Granted |  | 849,058 | ​ | ​ | 3.17 |  |  | ​ |  |
Exercised |  | — | ​ |  | — |  |  | ​ |  |
Forfeited |  | (93,256) | ​ |  | 3.24 |  |  | ​ |  |
Outstanding at December 31, 2023 |  | 755,802 | ​ | $ | 3.16 |  | 9.37 | ​ | $ | 24,729
Vested and expected to vest at December 31, 2023 |  | 755,802 | ​ | $ | 3.16 |  | 9.37 | ​ | $ | 24,729
Stock appreciation rights exercisable at December 31, 2023 |  | — | ​ | $ | — |  | — | ​ | $ | —
​ The aggregate intrinsic value of stock appreciation rights is calculated as the difference between the strike price of the stock appreciation rights and the fair value of the Company’s common stock for those stock appreciation rights that had strike prices lower than the fair value of the Company’s common stock. The weighted average grant-date fair value of stock appreciation rights granted during the year ended December 31, 2023 was $1.08 per share.

X
- References No definition available. + Details
Name: | us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration